We offer our registered users tailored information, free online courses and exclusive content.
Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?
... or you lost your password?
The conference “From hypertension to heart failure – Interruption of the cardiovascular continuum” organised by Serono Symposia International Foundation (SSIF) and held in Hanoi, Vietnam on 6-7 April, covered a broad spectrum from the value of beta-blockers, problems of adherence and non-medical approaches to reduce hypertension. The key slides from the meeting and the detailed medical report is available to all registered users of the EXCEMED website.
Cardiovascular diseases, the continuum of events from exposure to risk factors to occurrence of pathologic conditions, continue to increase in the Asia-Pacific region, along with the diffusion of a western life-style and its related metabolic disorders. As a result, hypertension, cardiac ischemic disease and heart failure, the world’s main cause of premature or sudden deaths and disabilities represent an increasing burden for its healthcare systems and professionals.
A continuous upgrading of scientific knowledge and skills, derived from evidence-based medicine and approved guidelines, is necessary to manage this emergency at every stage of its progression, especially when using different therapeutic approaches for different conditions. Serono Symposia International Foundation is proud to organize the 2013 Asia-Pacific Cardiology Symposium “From hypertension to heart failure – Interruption of the cardiovascular continuum”.
This symposium aims to re-examine recent achievements in the management of hypertension, coronary cardiac disease and chronic heart failure, also discussing prevention strategies for their complications, such as cardiac arrhythmias and cerebrovascular events, and it will also provide participants with solutions for optimizing patient care in daily clinical practice.
After attending this symposium, participants will receive updated knowledge on the management of hypertension, coronary artery disease and chronic heart failure, and so they will be able to:
The educational event «2013 Asia-Pacific Cardiology Symposium “From hypertension to heart failure - Interruption of the cardiovascular continuum” Hanoi, Vietnam on 6-7 April 2013» is accredited by the European Board for Accreditation in Cardiology (EBAC) for 9 (nine) hours of External CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME®), which is an institution of the European Union of Medical Specialists (UEMS).
Serono Symposia International Foundation designed this program in partnership with the Vietnam National Heart Association.
Saturday 6 April, 2013
Session I Improving cardiovascular risk reduction in the management of hypertension
Chair: Pham Gia Khai (Vietnam)
09.15 Tackling hypertension year 2012: effective blood pressure reduction according to current guidelines
Pham Nguyen Vinh (Vietnam)
09.45 The cardiovascular continuum – cardioprotective interventions by β-blockade.
Brian Tomlinson (China)
10.15 Beta Blockers are still considered the first line of therapy in essential hypertension?
Omar S. Awwad (Egypt)
11.15 Renin-angiotensin-aldosterone system (RAAS) inhibitors for mortality reduction in hypertension: a recent metaanalysis comparing ACEIs and ARBs.
Stefano Taddei (Italy)
11.45 BP control with fixed-dose combination therapy: where are we now?
Harry Struijker-Boudier (The Netherlands)
12.15 Case studies
Brian Tomlinson (China)
Session II Discussions on CAD treatments just emerged and role of sympathetic overactivity
Chair: Harry Struijker-Boudier (The Netherlands)
14.00 High heart rate in hypertension and coronary artery disease: is there clinical evidence for a benefit of heart rate reduction?
Pham Gia Khai (Vietnam)
14.30 Are beta-blockers ineffective in coronary artery disease? Critical assessment of the recent longitudinal, observational study of patients in the REACH registry.
Peter Yan (Republic of Singapore)
15.00 Long term use of aspirin for primary and secondary prevention: evidence and guidelines
Eugenio Reyes (The Philippines)
16.00 Sympathetic hyperactivity: sharing of pathophysiology for hypertension, CAD and CHF and their pharmacological approach
Dang Van Phuoc (Vietnam)
16.30 Novel non-pharmacological approaches for suppressing sympathetic activity: renal denervation and baroflex stimulators
Pham Manh Hung (Vietnam)
17.00 Case studies
Peter Yan (Republic of Singapore)
Sunday 7 April, 2013
Session III Update and practical guidance for heart failure and atrial fibrilation management
Chairs: Pham Gia Khai (Vietnam )and Ravi Kishore Amancharla Ganga (India)
08.30 The coming of atrial fibrillation from hypertension and CAD to CHF: placing beta- blockers in its prevention and management
Ho Huynh Quang Tri (Vietnam)
09.00 Benefits of β-blockade across patient types in CHF
Abdul Rashid Rahman (Malaysia)
09.30 Case studies
Abdul Rashid Abdul Rahman (Malaysia)
10.30 Traditional and new anti- thrombotic therapy in atrial fibrillation
Shirish M.S. Hiremath (India)
11.00 Update 2012 of the ESC heart failure guidelines: any new perspectives?
C. Sreenivas Gopal (India)
11.30 Diuretics in heart failure. Practical guidance for use
Piyamitr Sritara (Thailand)
Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of Serono Symposia International Foundation. All presentations represent solely the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
Pham Gia Khai Declared no potential conflict of interest.
Pham Nguyen Vinh Declared receipts of honoraria and consultation fees from: MSD, Astra-Zeneca, Servier, Abbott, Sanofi Aventis. Declared to be member of company advisory board, board of director, or other similar groups of: Astra-Zeneca. Declared to be stakeholder of Tam Duc Heart Hospital.
Brian Tomlinson Declared declared receipts of grants and contracts from: Bristol-Myers Squibb, Merck Serono, GlaxoSmithKline, Merck Sharp and Dohme, Novartis. Declared receipts of honoraria and consultation fees from: Amgen, Genzyme, Jannsen, Merck Serono. Declared to be member of company advisory board, board of directors or other similar groups of: Amgen, Genzyme, Jannsen, Merck Serono. Declared his participation in company sponsored speaker’s bureau of: Boehringer Ingelheim, Merck Serono, Merck Sharp and Dohme, Ranbaxy.
Omar S. Awwad Declared no potential conflict of interest.
Stefano Taddei Declared declared receipts of grants and contracts from: Boehringer Ingelheim, Servier, Novartis, Menarini. Declared his participation in company sponsored speaker’s bureau of: Servier, Pfizer, Recordati International, Novartis.
H.A.J. Struijker Boudier Declared receipts of grants and contracts form Servier. Declared receipts of honoraria and consultation fees from: Servier, Merck Serono, Durect. Declared to be member of company advisory board, board of director, or other similar groups of: Merck Serono, Serono Symposia International Foundation, Durect.
Peter Yan Declared no potential conflict of interest.
Eugenio B. Reyes Declared declared receipts of grant and contracts from Merck Serono. Declared receipt of honoraria from E. Merck, Merck Sharpe and Dohme, Astra-Zeneca, Novartis, Servier. Declared to be member of a company advisory board: Merck Serono and Novartis.
Dang Van Phuoc Declared no potential conflict of interest.
Nguyen Lan Viet Declared receipts of honoraria or consultation fees from: Astra-Zeneca, Servier, MSD.
Pham Manh Hung Declared receipts of honoraria or consultation fees from: Astra-Zeneca, Servier, MSD. Ravi Kishore Amancharla Ganga Declared no potential conflict of interest.
Ho Huynh Quang Tri Declared receipts of honoraria or consultation fees from: Novartis, Boehringer Ingelheim, Merck Serono, Astra-Zeneca.
Abdul Rashid Abdul Rahman Declared receipts research Grant from Merck Serono. Declared receipt of honoraria or consultation fees: from Merck Serono and Bayer. Declared participation in a company sponsored speaker’s bureau: MercK Serono, Servier, Sanofi Aventis, Bayer, MSD. Declared that his presentation include discussion of any off-labeled or otherwise non-approved uses of any product.
Shirish M.S. Hiremath Declared no potential conflict of interest.
Piyamitr Sritara Declared receipt of honoraria or consultation fees from: Astra Zeneca, Pfizer, Sanofi, MSD, Novartis, Takeda, Daiichi Sankyo, Berlinger INgelheim, Servier, Otsuka, Bayer, Sandoz, Medtronic. He declared his participation in: Astra Zeneca, Pfizer, Sanofi, MSD; novartis, Takeda, Daiichi Sankyo, Berlinger Ingelheim, Servier, Otsuka, Bayer, Sandoz, Medtronic sponsored speaker's bureau.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 22 March 2013.
C. Sreenivas Gopal
